70 articles
2seventy bio, Inc.
2seventy bio, Inc. was an immuno-oncology cell therapy company spun off from bluebird bio in 2021, best known as co-developer of the CAR T therapy Abecma.
A2 Biotherapeutics (company)
A2 Biotherapeutics, also known as HLA-A2, Inc., is a clinical-stage biotechnology company in Agoura Hills, California, developing logic-gated CAR T-cell therapies for solid tumors using its proprietary Tmod platform.
Acepodia
Acepodia is a clinical-stage biotechnology company in Alameda, California, founded in 2017 as a spin-off from Carolyn Bertozzi's Stanford lab, developing off-the-shelf cell therapies and antibody-drug conjugates for cancer.
Achilles Therapeutics
Achilles Therapeutics was a Stevenage, England-based clinical-stage biotechnology company developing personalized T-cell therapies for solid tumors; founded in 2016, it listed on NASDAQ in 2021 and was wound up in 2025.
Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, founded in 2014 and traded on Nasdaq as ACET.
AlloVir
AlloVir, formerly ViraCyte, was a Houston, Texas biotechnology company founded in 2013 that developed virus-specific T-cell therapies for immunocompromised patients before abandoning development in 2023.
Arcellx, Inc.
Arcellx, Inc., originally incorporated as Encarta Therapeutics in 2014, was a clinical-stage biotechnology company in Gaithersburg, Maryland, developing CAR-T cell therapies for cancer before Gilead Sciences acquired it in 2026.
Artiva Biotherapeutics
Artiva Biotherapeutics is a San Diego biotechnology company founded in 2019 as a spinout of South Korea's GC Cell, developing off-the-shelf allogeneic NK cell therapies and traded on Nasdaq since 2024.
Aspect Biosystems
Aspect Biosystems is a Vancouver biotechnology company founded in 2013 as a UBC spinout that develops bioprinted tissue therapeutics, led by an islet replacement therapy for type 1 diabetes.
Aurion Biotech
Aurion Biotech is a Seattle-based clinical-stage biotechnology company developing AURN001, a donor cell therapy for corneal edema, approved in Japan and majority-owned by Alcon since 2025.
Autolus Therapeutics plc
Autolus Therapeutics plc is a London-based, Nasdaq-listed biopharmaceutical company spun out of University College London in 2014; its CAR T therapy AUCATZYL, for adult leukemia, won FDA approval in November 2024.
Beiheng Bio (北恒生物)
Beiheng Bio (北恒生物), formally Nanjing Bioheng Biotech Co., Ltd., is a private Chinese biotech founded in Nanjing in 2017 that develops universal, CRISPR-engineered CAR-T cell immunotherapies for cancer.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals was a clinical-stage biotech that used its Chemical Induction of Dimerization platform to develop controllable cellular immunotherapies for blood cancers, solid tumors, and inherited blood disorders.
CARsgen Therapeutics
CARsgen Therapeutics (科济药业) is a Shanghai-based biopharmaceutical company, founded in 2014 and listed in Hong Kong, that develops CAR T-cell therapies for blood cancers and solid tumors.
Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company in Frederick, Maryland, developing mRNA-engineered CAR-T therapies for autoimmune diseases; its lead candidate, Descartes-08, is in Phase 3 for myasthenia gravis.
CellChina (西比曼)
CellChina (西比曼), also known as Cellular Biomedicine Group (CBMG), is a Shanghai-based clinical-stage company developing CAR-T, TCR-T, TIL, and stem-cell therapies for cancer and degenerative disease.
Cellular Biomedicine Group
Cellular Biomedicine Group was a clinical-stage biopharmaceutical company developing CAR-T immune-cell therapies for cancer, founded in 2009, Nasdaq-listed until its 2021 privatization, and renamed AbelZeta Pharma in 2023.
Celularity
Celularity Inc. is a cellular and regenerative medicine company in Florham Park, New Jersey, founded by Robert Hariri and Peter Diamandis in 2018 to develop placenta-derived therapies.
Century Therapeutics
Century Therapeutics is a Philadelphia-based, clinical-stage biotechnology company created by Versant Ventures in 2018 that develops allogeneic, off-the-shelf cell therapies for cancer and autoimmune disease from induced pluripotent stem cells.
CoRegen, Inc.
CoRegen, Inc. is a Houston biotechnology startup developing CRISPR-edited regulatory T-cell therapies for solid tumors, which received FDA clearance for its first trial in 2026.
CUTISS
CUTISS AG is a Zurich-based biotechnology company spun off from the University of Zurich in 2017 that develops personalized skin grafts, most notably denovoSkin for severe burns, now in Phase 3 trials.
Gameto, Inc.
Gameto, Inc. is a clinical-stage biotechnology company founded in 2020 by Dina Radenkovic and Martin Varsavsky, known for Fertilo, a stem-cell therapy that matures eggs outside the body to reduce hormone injections in IVF.
Gracell Bio
Gracell Bio, formally Gracell Biotechnologies Inc., was a Chinese clinical-stage biotech in Suzhou developing CAR-T cell therapies for cancer and autoimmune disease, acquired by AstraZeneca in 2024.
Gracell Biotechnologies (亘喜生物)
Gracell Biotechnologies (亘喜生物) was a Suzhou, China biotech founded in 2017 that developed CAR-T therapies for cancer and autoimmune disease and was acquired by AstraZeneca in 2024.
Grit Biotechnology (沙砾生物)
Grit Biotechnology (沙砾生物), branded GRIT Bio, is a Chinese clinical-stage cell-therapy company founded by Liu Yarong in 2019, developing tumor-infiltrating lymphocyte therapies for solid tumors.
Heyuan Bio (合源生物科技股份有限公司) (合源生物)
Heyuan Bio (合源生物科技股份有限公司) is a Chinese cell and gene therapy company founded in Tianjin in 2018, whose lead CAR-T therapy CNCT19 won NMPA approval in November 2023.
IASO Bio (驯鹿生物)
IASO Bio (驯鹿生物) is a Chinese biopharmaceutical company founded in 2017 and based in Nanjing and Shanghai, known for Fucaso, a BCMA-targeted CAR-T therapy for multiple myeloma approved in China in 2023.
IASO Biotherapeutics (驯鹿医疗)
IASO Biotherapeutics (驯鹿医疗) is a private Chinese cell-therapy company founded in Nanjing in 2017 by Zhang Jinhua, whose approved CAR-T therapy Fucaso treats relapsed multiple myeloma.
ImmPACT Bio
ImmPACT Bio USA Inc. was a West Hills, California, biotechnology company developing logic-gated CD19/CD20 CAR T-cell therapies for cancer and lupus, acquired by Lyell Immunopharma in 2024.
Imvax, Inc.
Imvax, Inc. is a clinical-stage biotechnology company in Philadelphia, spun out of Thomas Jefferson University in 2015, developing the personalized cell therapy IGV-001 for glioblastoma.